SCHEMBL7072991

SCHEMBL7072991

O=C(Nc1cccc2ccccc12)[C@@H]1CCN1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.67
MEN1 O00255 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
KDM4E B2RXH2 9/20 0.58
FABP7 O15540 2/20 0.55
GAA P10253 1/20 0.54
EPHX1 P07099 1/20 0.52
FABP3 P05413 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
MAPT P10636 3/20 0.49
HDAC8 Q9BY41 1/20 0.47
ALDH1A1 P00352 2/20 0.46
USP2 O75604 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072994 1.00 KMT2A (0.67) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL7075849 0.96 KMT2A (0.62) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL7075845 0.96 KMT2A (0.62) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL17676967 0.93 SMN1; SMN2 (0.62) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL10326974 0.93 SMN1; SMN2 (0.62) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL11119709 0.93 SMN1; SMN2 (0.62) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL31098661 0.81 HTR6 (0.60) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL14053676 0.80 KMT2A (0.57) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL14053679 0.80 KMT2A (0.57) KMT2AMEN1SMN1; SMN2KDM4EFABP7
SCHEMBL12348757 0.79 ROCK2 (0.48) KMT2AMEN1SMN1; SMN2KDM4EHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030120088-A1 Optically active azetidincarboxamide-coordinated transition metal complexes SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-26 US disclosed
EP-1319660-A1 Optically active azetidincarboxamide-coordinated transition metal complexes as catalysts in asymmetric reduction SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120088-A1 Optically active azetidincarboxamide-coordinated transition metal complexes AAAS, AP1M1, AP2A1 KMT2A 1593/4885MEN1 398/4885SMN1; SMN2 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.